Explore

ARPA-H Funds Teams to Advance On-Demand Genetic Medicine Manufacturing

ARPA-H Funds Teams to Advance On-Demand Genetic Medicine Manufacturing

The Advanced Research Projects Agency for Health (ARPA-H) has announced contract awards for its Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. This initiative aims to create an automated network capable of producing individualized, ribonucleic acid (RNA)-based genetic medicines on demand. The program seeks to replace the current slow, costly, and centralized manufacturing model with one designed for speed, scale, and reach. ARPA-H plans to invest up to $125 million in this research and development program. The goal is to develop automated manufacturing and real-time quality control into a distributed biomanufacturing network, allowing treatments to be made closer to the patient. This new paradigm is expected to empower communities nationwide to affordably produce cutting-edge treatments, rather than relying solely on major biomanufacturing hubs. The program will engage the U.S. Food and Drug Administration (FDA) to co-develop the necessary regulatory framework.

US Government Invests $125 Million in Personalized RNA Therapy Production Network

US Government Invests $125 Million in Personalized RNA Therapy Production Network

The U.S. Advanced Research Projects Agency for Health (ARPA-H) has allocated $125 million in funding to five groups to establish a network for producing 'made-to-order' RNA-based genetic medicines. This initiative, known as the Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, aims to transform the current slow, costly, and centralized manufacturing model into one that prioritizes speed, scale, and reach. The goal is to enhance access to new therapies for cancer, rare genetic conditions, and chronic diseases. The funding is distributed among Massachusetts General Hospital, Centillion Biosciences, HDT Bio, and Waterfall Scientific, which will focus on creating automated, distributed manufacturing platforms and quality control processes. A fifth group at the University of Utah will develop production quality control systems utilizing digital microfluidics, advanced optics, and AI to expedite medicine release.

N-Power Medicine Secures $32M Series B Funding to Expand Community Oncology Research

N-Power Medicine Secures $32M Series B Funding to Expand Community Oncology Research

N-Power Medicine Secures $32M Series B Funding to Expand Community Oncology Research

NIH-Funded Study Shows GLP-1 Treatment Extends Lifespan in Older Mice

NIH-Funded Study Shows GLP-1 Treatment Extends Lifespan in Older Mice

A National Institutes of Health (NIH)-funded study has revealed that the GLP-1 drug semaglutide extended the lifespan of older, healthy mice. Researchers at the University of California, Berkeley, administered semaglutide to 20-month-old female mice for three months, observing improvements in muscle and cognitive function. Gene expression analysis indicated a reduction in hallmarks of natural aging, such as increased inflammation and decreased regenerative capacity. Another group of mice treated until the end of life experienced a median lifespan nearly 100 days longer than untreated mice. The study compared the effects of semaglutide with calorie restriction, finding that the drug mimicked the anti-aging benefits of reduced food intake and offered additional advantages in certain areas. For instance, semaglutide-treated mice showed enhanced exploratory behavior, spatial memory, and blood-sugar maintenance, surpassing baseline levels. The study suggests that GLP-1 drugs may slow physiological aging itself,...

Aitia and Ono Pharmaceutical Partner to Advance Neurological Drug Discovery Using AI

Aitia and Ono Pharmaceutical Partner to Advance Neurological Drug Discovery Using AI

Aitia and Ono Pharmaceutical Partner to Advance Neurological Drug Discovery Using AI

Aging Clocks Show Promise for Longevity Interventions but Face Reliability Challenges

Aging Clocks Show Promise for Longevity Interventions but Face Reliability Challenges

Aging clocks, developed using machine learning techniques on biological data, are designed to predict age-related conditions and mortality risk. These clocks utilize various data types, including omics data, clinical chemistry results from blood tests, and imaging data. When applied to individuals, a higher predicted age compared to chronological age often correlates with increased mortality risk and the presence of age-related conditions. The primary goal for these aging clocks is to provide a rapid assessment tool for novel longevity interventions, potentially eliminating the need for lengthy, decade-spanning clinical trials. However, a significant challenge remains: ensuring the reliability of these clocks in assessing the efficacy of new interventions. There is currently no direct, well-mapped connection between the data used to derive these clocks and the underlying mechanisms of aging, making it difficult to predict whether a given clock will accurately estimate the effects of a treatment without ext...

FDA Issues Boxed Warning for Injectafer Due to Risk of Severe Hypophosphatemia

FDA Issues Boxed Warning for Injectafer Due to Risk of Severe Hypophosphatemia

The Food and Drug Administration (FDA) has mandated a boxed warning for ferric carboxymaltose injection, marketed as Injectafer, to highlight the risk of symptomatic hypophosphatemia (low phosphate levels in the blood). This is the agency's most stringent safety warning. The warning advises phosphate monitoring for patients at risk and those receiving repeat therapy within three months. Hypophosphatemia linked to Injectafer can lead to serious health issues, including hospitalization, prolonged phosphate replacement therapy, osteomalacia (bone softening), and fractures. The FDA's decision follows continued reports of symptomatic hypophosphatemia despite previous labeling updates in February 2020 and May 2023 that aimed to strengthen warnings about this risk. Data from the FDA’s Sentinel System indicates that serum phosphate testing occurs in less than 20% of Injectafer administration episodes, suggesting a gap in current monitoring practices.

VedaBio Partners with UCP Merchant Medicine to Integrate CRISPR Molecular Diagnostics into Urgent Care

VedaBio Partners with UCP Merchant Medicine to Integrate CRISPR Molecular Diagnostics into Urgent Care

VedaBio, a biotechnology company based in San Diego, California, has announced a multi-year partnership with UCP Merchant Medicine (UCPMM), a health system management company specializing in urgent care. This collaboration aims to position VedaBio's target amplification-free, CRISPR-based molecular diagnostics platform for the urgent care channel. The pre-launch groundwork will commence immediately, in anticipation of VedaBio's commercial launch, which is contingent upon FDA clearance. UCPMM, which serves 78 health system clients and over 300 urgent care centers across all 50 states, will leverage its extensive network and expertise to establish market expectations, performance benchmarks, training requirements, and pricing references for VedaBio's platform. The goal is to ensure the platform's successful integration into urgent care settings, addressing the significant unmet need for rapid, accurate, and accessible molecular testing in decentralized healthcare environments. Urgent care centers handle hund...

NexLife Expands Compounded GLP-1 Program with Microdose and Sublingual Options, Emphasizing Flat-Rate Pricing

NexLife Expands Compounded GLP-1 Program with Microdose and Sublingual Options, Emphasizing Flat-Rate Pricing

NexLife Expands Compounded GLP-1 Program with Microdose and Sublingual Options, Emphasizing Flat-Rate Pricing

CRISPR-Based Gene Therapy Shows Promise in Sustaining Lower Lipid Levels for a Year

CRISPR-Based Gene Therapy Shows Promise in Sustaining Lower Lipid Levels for a Year

Researchers have reported promising results from a small study involving a one-time CRISPR-based gene therapy shot that helped individuals with elevated cholesterol and triglyceride levels maintain significantly lower lipid levels for at least a year. Mel Mann, a patient advocate, highlighted this development, noting that the therapy represents a 'different model' compared to traditional treatments. The study, though small and involving severe cases, demonstrated that the highest dose of the CRISPR shot reduced LDL cholesterol and triglycerides by approximately half, with the effects sustained over the year. This suggests a potential for a durable therapeutic intervention for lipid management through gene editing.

Study Identifies Dietary Keys to Protecting the Aging Brain, Shifting Alzheimer's Research Focus

Study Identifies Dietary Keys to Protecting the Aging Brain, Shifting Alzheimer's Research Focus

A study published in the journal Nutrients, led by assistant professor Samitinjaya Dhakal of South Dakota State University, provides evidence that diets rich in fiber and specific micronutrients are linked to sharper memory and better brain health in adults over 65. The research analyzed dietary patterns and cognitive performance in 72 older adults, revealing that higher intake of dietary fiber, healthy unsaturated fats, and key micronutrients like vitamins A and E, magnesium, and potassium, were consistently associated with improved brain function. Carotenoids, potent antioxidant compounds found in vibrant fruits and vegetables, also showed a positive association. Conversely, the study highlighted a widespread 'nutrition gap' among participants, with many older adults lacking these brain-protective nutrients while consuming high amounts of refined grains, which were negatively associated with cognitive function. This research contributes to a growing shift in Alzheimer's research, moving away from a prima...

Novo Nordisk Seeks U.S. Approval for CagriSema to Diversify Beyond Semaglutide

Novo Nordisk Seeks U.S. Approval for CagriSema to Diversify Beyond Semaglutide

Novo Nordisk Seeks U.S. Approval for CagriSema to Diversify Beyond Semaglutide